GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » Mohanram G-Score

Magenta Therapeutics (Magenta Therapeutics) Mohanram G-Score : N/A (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics Mohanram G-Score?

Magenta Therapeutics does not have enough data to calculate Mohanram G-Score.


Magenta Therapeutics Mohanram G-Score Historical Data

The historical data trend for Magenta Therapeutics's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magenta Therapeutics Mohanram G-Score Chart

Magenta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Mohanram G-Score
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Magenta Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Magenta Therapeutics's Mohanram G-Score

For the Biotechnology subindustry, Magenta Therapeutics's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magenta Therapeutics's Mohanram G-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's Mohanram G-Score falls into.



Magenta Therapeutics Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Magenta Therapeutics  (NAS:MGTA) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Magenta Therapeutics Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Magenta Therapeutics (Magenta Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.
Executives
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr officer: CHIEF ACCOUNTING OFFICER 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz officer: CHIEF FINANCIAL OFFICER 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng director 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa officer: Chief Medical Officer 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp director 2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia director, officer: CEO and President C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness officer: See Remarks C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles director C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140

Magenta Therapeutics (Magenta Therapeutics) Headlines

From GuruFocus

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

By sperokesalga sperokesalga 03-31-2023

FMR LLC Acquires New Stake in Magenta Therapeutics Inc

By GuruFocus Research 11-14-2023